汉森制药(002412) - 2024年1月11日投资者关系活动记录表

Group 1: Company Overview - Hunan Hansen Pharmaceutical Co., Ltd. is actively engaging with investors through various activities, including analyst meetings and online research [2] - The company is focusing on promoting its flagship products, including the "Hansen Simiao Decoction" and "Tianma Xingnao Capsule," which have shown significant sales growth [3] Group 2: Product Performance - The "Tianma Xingnao Capsule" reported a sales revenue increase of 26.33% in the first half of 2023 compared to the same period last year, indicating strong growth potential [3] - The company aims to enhance the brand image and sales of the "Hansen Simiao Decoction" by increasing promotional efforts [3] Group 3: Strategic Initiatives - The company is investing in the Hunan Hansen Health Industry Park project, which integrates traditional Chinese medicine cultivation, research, and tourism [4] - Plans are in place to optimize product structure and expand the market for leading products while investing in other quality products to achieve sales breakthroughs in 2024 [4] Group 4: Market Challenges and Responses - The company is addressing fluctuations in raw material prices by standardizing procurement processes, utilizing local supply chains, and maintaining its own cultivation bases [3] - Continuous monitoring of medicinal material prices will inform inventory adjustments to mitigate cost impacts [3]